International Clinical Trial: A single-center, single-arm clinical study of the efficacy and safety of iparomlimab and tuvonralimab combined with lenvatinib as second-line/rear line treatment for locally advanced or metastatic renal cell carcinoma

Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124272) titled 'A single-center, single-arm clinical study of the efficacy and safety of iparomlimab and tuvonralimab combined with lenvatinib as second-line/rear line treatment for locally advanced or metastatic renal cell carcinoma' on May 9.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Qilu Hospital of Shandong University

Condition: Cell carcinoma

Intervention: Treatment group:Lenvatinib 14mg, once daily (QD), orally, continuous medication

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-05-10

Target Sample Size: Treatment group:45;

Countries of Recruitmen...